-
Guest - w'd love to know what you think about the forum! Take the 2025 Survey »
Libre 3
- Thread starter onnecar
- Start Date
D
Deleted member 527103
Guest
You can check on the freestyle Libre website https://www.freestylelibre.co.uk
I understand it is only available on prescription in England (I do not know about the rest of the UK) and has stricter criteria than the Libre 2.
If you use the search function at the top right of every page, you will find more details.
I understand it is only available on prescription in England (I do not know about the rest of the UK) and has stricter criteria than the Libre 2.
If you use the search function at the top right of every page, you will find more details.
onnecar
Well-Known Member
- Messages
- 173
- Location
- Melksham
- Type of diabetes
- Type 2
- Treatment type
- Tablets (oral)
- Dislikes
- Football, Icy weather, Getting old.
I think you're right that it is only available on prescription. It doesn't even bring libre 3 up on a search. Hopefully it will soon be available to purchase. It's a continuous reading and also much smaller.
Last edited:
barrym
Well-Known Member
Does anyone know for definite it is available on prescription and where? I can find evidence that it is an approved (?) device on the NHS, but none that it is prescribable. Certainly not on my CCG Formulary anyway.
D
Deleted member 527103
Guest
This was mentioned on another Libre 3 thread. It is included in the NICE recommendation under the same category as Dexcom G6 rather than the Libre 2. So it cannot be prescribed by a GP.
(At least that is the case in England as the rules are different in Wales, Scotland and NI.)
Sorry, I am on my phone so cannot search all the threads but I remember reading it this week.
barrym
Well-Known Member
My consultant seemed to suggest that it will be available for GP to prescribe once it has fought through the NHS treacle.
Just can't believe it's taking so long.
Just can't believe it's taking so long.
For anyone who lives in Greater London, on 5 October 2022 the NHS London Clinical Network for Diabetes (a group consisting of clinicians, patients and system partners) issued guidance ("A pan-London implementation document for continuous glucose sensors for adults with T1 diabetes: written pathway") to all integrated care boards and secondary care to indicate how the new NICE guidelines NG17, issued on 1st April 2022, ought to be implemented in London.
As far as the Libre 3, Dexcom G7, Dexcom G6 are concerned, the guidance issued says that if a diabetic patient demonstrates (a) problematic hypoglycaemia, or (b) is pregnant and has problematic hypoglycaemia, or (c) is using or will in the future use an automated insulin delivery system/closed loop/insulin pump where the cgm is (or will be) compatible with the insulin delivery system, etc and/or (d) there is a clinical need to have a family member, friend or other carer have access to their glucose data, then clinicians should consider offering patients access to the appropriate cgm.
"Problematic hypoglycaemia" is defined in the guidance as either:
1. One or more episodes of severe hypoglycaemia in the preceding 12 months; and/or
2. Impaired hypoglycaemia awareness (score ≥ 4 Gold score); and/or
3. More than one episode of asymptomatic hypoglycaemia per week;
4. Fear of hypoglycaemia
The guidance goes on to indicate that those who don't fall within the above criteria should be offered other continous glucose monitors or flash glucose monitors which are available on prescription.
They have included a very useful flowchart that suggests the decision -making process.
This guidance has apparently been rolled out to the various Greater London ICBs and secondary care.
It will be interesting to see to what extent this guidance is adopted outside Greater London.
As far as the Libre 3, Dexcom G7, Dexcom G6 are concerned, the guidance issued says that if a diabetic patient demonstrates (a) problematic hypoglycaemia, or (b) is pregnant and has problematic hypoglycaemia, or (c) is using or will in the future use an automated insulin delivery system/closed loop/insulin pump where the cgm is (or will be) compatible with the insulin delivery system, etc and/or (d) there is a clinical need to have a family member, friend or other carer have access to their glucose data, then clinicians should consider offering patients access to the appropriate cgm.
"Problematic hypoglycaemia" is defined in the guidance as either:
1. One or more episodes of severe hypoglycaemia in the preceding 12 months; and/or
2. Impaired hypoglycaemia awareness (score ≥ 4 Gold score); and/or
3. More than one episode of asymptomatic hypoglycaemia per week;
4. Fear of hypoglycaemia
The guidance goes on to indicate that those who don't fall within the above criteria should be offered other continous glucose monitors or flash glucose monitors which are available on prescription.
They have included a very useful flowchart that suggests the decision -making process.
This guidance has apparently been rolled out to the various Greater London ICBs and secondary care.
It will be interesting to see to what extent this guidance is adopted outside Greater London.
